ClinicalTrials.gov
Cure8 trial brief
Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
Diet and lifestyle
Biomarkers
Fecal calprotectin
Clinical Trial Phase 1
Adult patients
Teens
Clinicians
Researchers
Why This Matters
Dietary approaches that reduce gut inflammation could offer a low‑risk option to help manage symptoms and biomarkers in Crohn’s disease. This trial specifically tests a catered anti‑inflammatory diet and measures fecal calprotectin to assess inflammation.
Who Should Pay Attention
People with mild-to-moderately active Crohn’s disease (ages 16–75) interested in dietary interventions, caregivers, clinicians who manage IBD, and researchers studying diet and biomarkers in IBD.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment122 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This trial is an interventional study evaluating whether a tailored anti-inflammatory diet can reduce intestinal inflammation and improve symptoms in Crohn’s disease over an 8‑week period. Meals are provided (twice weekly delivery) so participants follow a controlled dietary pattern during the intervention.
The record lists fecal calprotectin as a key biomarker and eligibility requires evidence of active inflammation and stable medications.
If you’re considering participation, note key exclusions: prior bowel resection, complicated Crohn’s (recent stricturing/penetrating disease or draining perianal fistula), current pregnancy/breastfeeding, recent infections, use of certain diets or probiotics, and other health conditions that could limit following the diet.
Recruitment site listed is University of Miami.
Keep In Mind
This is a registered interventional clinical trial (recruiting) rather than a published trial result. Outcomes and effects are not reported in this record. The registry entry defines eligibility and exclusion criteria that limit applicability (e.g., excludes complicated Crohn’s and recent bowel resection).
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of Miami
Trial IDNCT07671872
Study typeInterventional
Trial phaseNA
Enrollment122 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 24, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Two Dietary Fibers May Cut Crohn’s Risk in Certain Patients
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease
This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...
Physical Activity and Fitness in Pediatric Inflammatory Bowel Disease
Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...